The urgent need for improved vaccines in the Chinese market was made clear in recent weeks as the Chinese media reported the tragic news of several babies that died after they received hepatitis B vaccines made by a local manufacturer. There are big opportunities for the developers of improved safe...
Read more
Monthly Archives: December 2013
Dynamix Partners with Teva Spinoff
Teva spinoff CleveXel Pharma is partnering with small molecule-focused Israeli firm Dynamix Pharmaceuticals to develop a dual-mechanism SYK/JAK molecule, DNX-04042, in rheumatoid arthritis (RA). The product, which is orally active, is Dynamix’ lead development program. Through this collaboration, the companies hope to bring the RA project to The thinking a...
Read more
BioLine RX Celiac Trial
BioLineRx (NASDAQ: BLRX; TASE: BLRX) has enrolled the first patient in a Phase 1/2 trial of BL-7010, for the treatment of celiac disease. The first patient was enrolled at Tampere Hospital in Finland. The Phase 1/2 study is a two-part (single and repeated), double-blind, placebo-controlled, dose escalation study of BL-7010...
Read more
Kadimastem Gets NIS 8.5 M for Stem Cells
Kadimastem (TASE:KDST), a developer of human pluripotent stem cell-based drug screening and therapeutic solutions, has received approval for a budget from the OCS for two development plans totaling NIS 8.5 million, for the development of cell therapy and drug screening solutions for diabetes, as well as for the development of...
Read more
Pluristem Deal With S. Korea
Pluristem Therapeutics Inc. (NasdaqCM: PSTI; TASE: PLTR) has issued to South Korea-based CHA Bio&Diostech (Kosdaq:CHA) shares of its common stock at a price of $4.16 per Pluristem common share, a premium of 26% over the closing price on December 16, 2013. The shares are subject to a lock up period...
Read more
CollPlant Raises NIS 3.7 M
CollPlant Holdings Ltd. (TASE: CLPT) has raised NIS 3.7 million (about $1 million) at a price of 23% above the minimum set due to surplus demand from institutions and the public at NIS 0.37 (about 0.10 Cent) per share with an issue that was 4.5 times oversubscribed. Collplant produces human...
Read more
Gene Synthesis Provider to Debut at Biotech China
GenScript , the largest gene synthesis provider in the U.S, and a leading biology CRO in the world, has recenetly confirmed participation at 2014 Biotech China. GenScript is a leading biology CRO focusing exclusively on early drug discovery and development services. Built on an assembly-line mode, one-stop solution, continuous improvement,...
Read more
Cell Cure Gets Grant for AMD
Cell Cure Neurosciences Ltd. has been awarded a grant of NIS 6.1 million for 2014 from the Office of the Chief Scientist at Israel’s Ministry of Economy. The grant will help finance the development of OpRegen, a cell-based therapeutic product for the treatment of age-related macular degeneration. The dry form...
Read more